Onconova's myelodysplastic syndrome drug enters Phase III trial

05/12/2013 | Pharmaceutical Business Review Online

Onconova Therapeutics has finished enrolling 270 myelodysplastic syndrome patients for a late-stage trial of rigosertib. The trial will be carried out in the U.S. and five countries in the European Union, with overall survival as main endpoint. The firm expects to release data either in the fourth quarter of this year or the first quarter of next year.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI